Autolus presents 2026 net product revenue outlook of at least $150 million
AUTL•Autolus Therapeutics expects 2026 net product revenue of at least $150 million, the top of its prior guidance range. Third-quarter revenue rose 95% to $41.2 million, while nine-month revenue increased 122% to $113.1 million.
1. Revenue outlook and results
Autolus Therapeutics expects 2026 net product revenue of at least $150 million, the top of its prior guidance range. Third-quarter Aucatzyl net product revenue rose 95% to $41.2 million, and nine-month net product revenue increased 122% to $113.1 million. Manufacturing success exceeds 90%, with no capacity limitations. Its Phase 2 pediatric leukemia trial CATULUS is enrolling, with data expected at the end of 2027.




